Last reviewed · How we verify
Gonapeptyl®
Gonapeptyl is a GnRH (gonadotropin-releasing hormone) agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to reduced sex hormone production.
Gonapeptyl is a GnRH (gonadotropin-releasing hormone) agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to reduced sex hormone production. Used for Prostate cancer (hormone-sensitive), Endometriosis, Uterine fibroids.
At a glance
| Generic name | Gonapeptyl® |
|---|---|
| Sponsor | University Hospital, Ghent |
| Drug class | GnRH agonist |
| Target | GnRH receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology; Endocrinology |
| Phase | FDA-approved |
Mechanism of action
As a GnRH agonist, Gonapeptyl binds to GnRH receptors in the pituitary gland, initially causing a surge in LH and FSH release (flare effect), followed by sustained suppression of these hormones through receptor desensitization. This results in profound suppression of testosterone in males and estrogen in females, making it useful for hormone-dependent conditions.
Approved indications
- Prostate cancer (hormone-sensitive)
- Endometriosis
- Uterine fibroids
- Precocious puberty
Common side effects
- Hot flashes
- Decreased libido
- Erectile dysfunction
- Injection site reactions
- Headache
- Bone density loss (with prolonged use)
Key clinical trials
- PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study (PHASE4)
- Mild Stimulation Protocol Using Clomiphene Citrate for Women With PCOS Undergoing in Vitro Fertilization (PHASE4)
- Luteal Phase Support in Insemination Cycles (PHASE4)
- Ovarian Stimulation Using Recombinant Follicle-stimulating Hormone (FSH) and Gonadotrophin Releasing Hormone (GnRH) Agonist in Alternate Days (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gonapeptyl® CI brief — competitive landscape report
- Gonapeptyl® updates RSS · CI watch RSS
- University Hospital, Ghent portfolio CI